Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2013

View Archived Issues

New biomarkers for celiac disease reported

Researchers prepare and test labeled iRGD peptides as cancer diagnostics

Phase I evaluation of oligonucleotide therapy in patients with ALS

Dainippon Sumitomo Pharma presents novel selective 11-beta-HSD1 inhibitor

New CCR1 and CCR6 receptor inhibitors for the treatment of rheumatoid arthritis described

Results presented from head-to-head phase II study of pateclizumab versus adalimumab

Roche presents final stage 1 results from obinutuzumab study

Portola Pharmaceuticals patents novel tyrosine-protein kinase inhibitors

Merck KGaA discloses new protein kinase inhibitors

Johnson & Johnson to acquire Aragon Pharmaceuticals

Inovio Pharmaceuticals reports data from preclinical trial of its H7N9 DNA vaccine

Oxygen Healthcare Research divulges novel histamine H3 receptor ligands

Ambrx and Zhejiang Medicine collaborate on ARX-788 for breast cancer

Shionogi to collaborate with Irish universities

Athera Biotechnologies obtains E.U. grants for its antibody therapy

EryDex obtains orphan drug designation for ataxia telangiectasia in Europe

Aeroquin shows sustained therapeutic efficacy in phase III trial for cystic fibrosis

MannKind completes phase III study of Afrezza in type 2 diabetes

Eli Lilly exercises rights to Transition Therapeutics' TT-401

Nitto Denko's lidocaine patch receives additional indication approval in Japan

Abilify granted additional indication approval as adjunctive therapy for depression

Summit achieves milestone in development of C. difficile antibiotic

Silence Therapeutics advances phase Ib/IIa study of RNAi therapeutic

FDA accepts Ruconest BLA for review

Takeda launches Nesina and fixed-dose combinations for type 2 diabetes in the U.S.

Canadian acceptance of MycoTool for release testing of Roche product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...